End-Stage Renal Disease Market – Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

End-Stage Renal Disease Market – Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The end-stage renal disease market is expected to witness a CAGR of around 10% during the forecast period (2022-2027).

The current coronavirus disease 2019 (COVID-19) pandemic is forcing unprecedented changes in daily life people. Many patients are under lockdown during this time, and the nephrology community has been forced to adapt quickly to this new reality. Patients on dialysis are at high risk of COVID-19 exposure due to the widespread use of public transportation and densely packed clinical spaces. Under the 2018 Bipartisan Budget Act, the Centers for Medicare & Medicaid Services (CMS) allowed patients on home dialysis to choose to have their monthly end-stage renal disease (ESKD) clinical assessments through telehealth, resulting in an increased demand for home dialysis in United States. According to a report published in April 2020, the Rogosin Institute, an independent dialysis provider affiliated with New York-Presbyterian Hospital with a home dialysis population of 210 patients, out of which 150 were on peritoneal dialysis (PD) and 60 on home hemodialysis (HHD). COVID-19 has a major impact on the kidney of patients. According to the National Kidney Foundation, in April 2020, 37% of COVID-19 cases involve the kidneys, and acute kidney diseases have an incidence of 50% in hospitalized COVID-19 patients. Thus COVID-19 is expected to drive the demand for the market during the pandemic period.

The end-stage renal disease market is driven by the increasing number of patients suffering from chronic kidney disease. According to the article titled " Epidemiology of Chronic kidney disease: an update 2022 " published in April 2022, approximately 10% of the global population suffers from chronic kidney disease, and millions die each year. The rate of patients with chronic kidney disease is increasing. According to the report published in The Lancet Journal in February 2020, over 40% of people required dialysis with severe chronic kidney disease.

Another factor is the introduction of technologically advanced products, like low-maintenance dialysis equipment and artificial kidney. In March 2021, Baxter International Inc. announced United States Food and Drug Administration (US FDA) clearance of its next-generation Artificial Kidney 98 dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. This indicated that companies are taking initiatives to establish a strong footprint and launch technologically advanced products in the market.

Additionally, there is a higher prevalence rate for diabetes, which leads to cause end-stage renal disease in the long run, which may drive the market growth. According to the International Diabetes Federation, in 2021, around 537 million adults (20-79 years) were living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 by 2045. Diabetes is one of the leading causes of kidney failure, which is likely to drive the market studied over the forecast period.

However, the delay in diagnosing chronic kidney disease may restrain the market growth over the forecast period.

Dialysis is a procedure that removes waste products from the blood, such as urea and creatinine, as a result of inadequate kidney function. It is frequently required for persons with chronic renal failure. The blood is cleansed, and extra fluid and toxins are eliminated during this operation.

Moreover, the demand for dialysis is expected to increase as the incidence of end-stage renal disease tremendously increases, worldwide. The prevalence of end-stage renal disease (ESRD) is high and increasing at a significant rate. According to the article titled "Kidney Disease Statistics for United States" published in 2021 nearly 786,000 people in United States were living with ESRD with 71% on dialysis and 29% with a kidney transplant. Meanwhile, the number of patients who initiated peritoneal dialysis and who received a preemptive transplant reached an all-time high of 18,631. Additionally, funding for dialysis is rising in United States, according to the American Society of Nephrology.

The end-stage renal disease market is growing, as the population increases, globally, thus, raising funding for better dialysis products and services. For instance, on July 1, 2021, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule for the Prospective Payment System (PPS) for renal dialysis services. Under the ESRD PPS for 2022, Medicare is expected to pay USD 8.9 billion to approximately 7,700 ESRD facilities for furnishing renal dialysis services.

On the other hand, the high prevalence of diabetics, hypertension, rising incidences of kidney failures, lack of kidney donors for transplantation, tedious kidney transplant procedure, and increasing demand for home peritoneal dialysis treatment, thus, all factors put together drive the segmental growth over the forecast period.

Asia Pacific is expected to witness high growth in end-stage renal disease due to the presence of high disposable income and the high acceptance rate of technologically improved products. Moreover, high blood pressure and diabetes cases in Asia Pacific may contribute to market growth. According to the Asian Diabetics Prevention Initiatives, in 2020, 60% of the diabetic population in the world live in Asia. With a higher contribution of China and India, which is 113.9 million and 65.1 million adults with diabetes in China and India respectively, and by 2030, both China and India combined may have almost half a billion diabetic patients.

Additionally, growing patient affordability, aging population, lifestyle stress, a broad population base, improving diagnosis quality may fuel the market growth. According to a report published by the national health portal of the Indian Government estimates that every year about 2.2 lakh new patients of end-stage renal disease (ESRD) are increasing, resulting in demand for 3.4 crore dialysis every year. Approximately 4,950 dialysis centers were available, largely in the private sector in India. The presence of a large number of dialysis centers in this region and a rise in the number of patients with chronic renal and kidney diseases are expected to boost the market growth.

The market studied is a fragmented market owing to the presence of many major market players. Market players adopt the strategies, such as organic growth strategies (treatment type launches, treatment type approvals) and others (such as patents and events), which are being prioritized by corporations with inorganic growth strategies, like acquisitions, partnerships, and collaborations. Some of the market players are Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc., Medtronic PLC, B Braun Melsungen AG, Asahi Kasei Medical Co. Ltd, Cantel Medical, Nikkiso Co., etc.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support